Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Book/Report

Best Practices in Developing Proprietary Names for Human Prescription Drug Products Guidance for Industry.

Best Practices in Developing Proprietary Names for Human Prescription Drug Products Guidance for Industry. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; December 2020.

Save
Print
December 23, 2020

Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; December 2020.

Look-alike and sound-alike names weaken the safety of medication use. This guidance provides a structure for industry to reduce instances of drug name similarities and describes the US Food and Drug Administration (FDA) vetting process for drug names to improve naming actions prior to submission to the agency.

Save
Print
Cite
Citation

Best Practices in Developing Proprietary Names for Human Prescription Drug Products Guidance for Industry. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; December 2020.